- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01079897
Efficacy and Safety of an Ectoine-containing Cream in the Treatment of Mild to Moderate Atopic Dermatitis
October 17, 2011 updated by: Bitop AG
A Randomized, Comparator-controlled, Double-blind, Multicenter Intra-individual Clinical Trial to Evaluate the Efficacy and Safety of an Ectoine-containing Cream in the Treatment of Mild to Moderate Atopic Dermatitis
This study evaluates the efficacy of the topical used ectoine-formulation EHK02-01 compared to Atopiclair.
Patients are examined at visit 2 (baseline visit).
The patient topically applies EHK02-01 or Zarzenda® twice daily on two symmetric lesional areas over 28 days.
Response to therapy is recorded at each visit.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 13507
- Hautarztzentrum Tegel
-
Freiburg, Germany, 79100
- Hautarztpraxis
-
Mahlow, Germany, 15831
- Gemeinschaftspraxis Mahlow
-
Potsdam, Germany, 14469
- Haut- und Lasercentrum Potsdam
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Female or male individuals between 18 and 65 years in good general health diagnosed atopic dermatitis for ≥ 6 months, in active stage (active stage means severity as measured by overall IGA-Score between 1 and 4)
- At least two comparable areas of stable atopic eczema on bilateral symmetric corresponding sides of the extremities or the body (except for head and genital area), each of at least 10 cm², with a modified, objective local SCORAD of the test areas > 5
- Both lesional areas of interest must have a difference in the modified, objective local SCORAD of ≤ 3
- Willingness to adhere to the schedule of the investigation, concomitant therapy prohibitions, restrictions, treatment regimen and procedures described in the CIP
- Written informed consent to participate in the trial, prior to any investigation related procedures, indicating an understanding of the purpose of the clinical investigation
- A patient of childbearing potential agrees to use a contraceptive methods for the duration of the investigation according to CPMP/ICH 286/95 note 3
Exclusion Criteria:
- Patients who are self-reported to be pregnant, nursing or planning pregnancy during the clinical investigation
- Patients with any skin disease that in the investigator's opinion may interfere with the conduct of the study or the evaluation of the results (e.g. psoriasis)
- Patients with a known malignancy
- Presence of any disease and/or condition and/or history of diseases and/or conditions that according to the investigator may interfere with the conduct of the investigation or the evaluation of the results (such as abnormal laboratory values, chronic inflammatory dis-eases, immunosuppressive diseases, autoimmune diseases, liver or kidney diseases, severe infectious diseases)
- Patients who did not respect the wash-out periods prior to and during the clinical investigation
- Vaccination within 6 days prior to enrolment and during the study.
- Patients with a known allergy against any ingredient of the test products
- Patients who are known to have had a substance abuse (drug or alcohol) problem within the previous 12 months
- Patients who participate in another clinical trial or have participated in another clinical trial within the last 30 days prior to the first day of investigation
- Patients who are involved in the organization of the clinical investigation
- Patients that are in any way dependant on the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Atopiclair
|
topical applied cream, twice daily
Other Names:
|
EXPERIMENTAL: EHK02-01
Ectoine containing cream
|
topical applied cream containing 7% ectoine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
change of a modified, objective (local) SCORAD
Time Frame: 28 days
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change of local IGA
Time Frame: 28 days
|
28 days
|
Change of Pruritus
Time Frame: 28 days
|
28 days
|
Patient's judgment on efficacy
Time Frame: 28 days
|
28 days
|
AEs during treatment phase
Time Frame: 28 days
|
28 days
|
Physical examination
Time Frame: 28 days
|
28 days
|
Patient's assessment of tolerability and safe
Time Frame: 28 days
|
28 days
|
change of the modified, objective local SCORAD
Time Frame: 7 days
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Wolfgang Vanscheidt, Professor, Professor Dr. med Wolfgang Vanscheid (Hautarzt, Allergologie, Phlebologie)
- Principal Investigator: Tanja Fischer, Dr., Haut- und Lasercentrum Potsdam
- Principal Investigator: Martin Miehe, Dr., Hautarztzentrum Tegel
- Principal Investigator: Michael Sebastian, Dr., Facharzt für Dermatologie
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2010
Primary Completion (ACTUAL)
June 1, 2010
Study Completion (ACTUAL)
June 1, 2010
Study Registration Dates
First Submitted
March 2, 2010
First Submitted That Met QC Criteria
March 2, 2010
First Posted (ESTIMATE)
March 3, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
October 18, 2011
Last Update Submitted That Met QC Criteria
October 17, 2011
Last Verified
October 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 133-002
- 0010287 (REGISTRY: DIMDI)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild to Moderate Atopic Dermatitis
-
Wake Forest University Health SciencesActive, not recruiting
-
MEDA PHARMA SPA, a Viatris companyNot yet recruitingMild to Moderate Atopic Dermatitis
-
Creabilis SATerminated
-
HK inno.N CorporationNot yet recruiting
-
Greenpharma S.A.S.Complife Italia S.r.lCompletedMild to Moderate Atopic DermatitisItaly
-
HanAll BioPharma Co., Ltd.CompletedMild to Moderate Atopic DermatitisUnited States
-
BayerCompletedMild to Moderate Atopic DermatitisGermany
-
Sterna Biologicals GmbH & Co. KGCompletedMild to Moderate Atopic DermatitisGermany
-
Regeneron PharmaceuticalsSanofiCompletedModerate to Severe Atopic Hand and Foot DermatitisUnited States, Germany, Japan, Poland
-
SanofiRegeneron PharmaceuticalsRecruitingModerate to Severe Atopic DermatitisCanada
Clinical Trials on Atopiclair
-
Johnson & Johnson Consumer and Personal Products...CompletedAtopic DermatitisUnited States
-
Wake Forest University Health SciencesCompletedAtopic DermatitisUnited States
-
Pierre Fabre MedicamentCompletedAtopic DermatitisFrance, Romania, Estonia, Poland, Lithuania